Join us for an in-depth discussion about Alzheimer’s Disease, the unmet need and how Cyclo Therapeutics is working to advance a treatment.
Featured Speaker:
![Lemere-400x520[55].jpg](https://static.wixstatic.com/media/094bb2_10cbc35f3f834fe8962ce380d55c5eee~mv2.jpg/v1/crop/x_56,y_42,w_314,h_408/fill/w_155,h_201,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/Lemere-400x520%5B55%5D.jpg)
Members of Management:
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a late clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease.
The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is being studied in a Phase 3 pivotal clinical trial for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning a Phase 2 clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.
For additional information, visit the Company’s website: www.cyclotherapeutics.com.